Selegiline in Cats: Is It Used, What's Known, and Why Evidence Is Limited

Selegiline is a prescription monoamine oxidase inhibitor (MAOI) that can affect brain neurotransmitters involved in behavior and attention. In veterinary medicine it is better known for use in dogs, so it often comes up when families notice senior-cat confusion and search for options.

Because cat-specific evidence is limited, the most useful question is not “does it work,” but “is it appropriate for this cat after medical causes and interactions are checked?”

Yes, some veterinarians do use selegiline in cats, but it is typically a selegiline off label cats situation rather than a routine, label-backed choice. Off-label use means the veterinarian is applying medical judgment based on available science, experience, and the individual cat’s risks.

That is why follow-up and careful monitoring are part of the decision, not optional extras.

Anipryl is a brand name for selegiline that many people recognize from canine cognitive dysfunction care. When owners say “anipryl for cats,” they are usually asking whether the same drug concept can apply to feline cognitive dysfunction.

The key point is that brand familiarity does not equal feline proof. A veterinarian still needs to decide whether selegiline is reasonable for that specific cat and medication list.

Selegiline blocks enzymes (monoamine oxidases) that break down certain brain chemicals. At lower exposures it is relatively more MAO-B selective, which is one reason it is discussed in conditions involving dopamine signaling(Unknown, 2017).

Mechanism is not the same as outcome, especially in cats. A veterinarian uses the mechanism as one piece of the puzzle, alongside the cat’s symptoms, other diseases, and potential interactions.

Direct, high-quality clinical evidence in pet cats is limited. Much of what people cite comes from other species, including laboratory models and human neurology literature, which can suggest possible pathways but does not confirm benefit in cats.

That is why veterinarians often frame selegiline as a cautious trial with clear goals, rather than a guaranteed cat dementia medication.

Feline cognitive dysfunction is underrecognized, and it is hard to measure consistently. Owners care about real-life function—sleep, litter box reliability, and reduced distress—while studies need standardized scoring tools and consistent case definitions.

Cats also have many common “look-alike” illnesses, so studies must carefully rule out pain, thyroid disease, kidney disease, and hypertension to avoid mixing different problems together.

Owners often notice nighttime vocalizing, wandering without a clear goal, getting stuck in corners, or seeming confused in familiar rooms. Litter box “near misses” and changes in social behavior can also appear.

These signs are not proof of dementia. They are a reason to schedule a senior-cat evaluation so medical causes and pain are not missed before any feline cognitive dysfunction treatment is discussed.

Arthritis pain can cause litter box avoidance or irritability. Hyperthyroidism can cause restlessness and vocalizing. Kidney disease can change sleep patterns and appetite. Vision or hearing loss can make a cat seem “confused” when they are actually struggling to sense their environment.

Because these are common and often treatable, veterinarians usually prioritize ruling them out before trying a cat dementia medication.

Many veterinarians start with a physical exam and baseline lab work, often including thyroid testing, kidney values, and urine testing. Blood pressure checks are also common in older cats, because hypertension can affect behavior and vision.

The goal is a safer, more targeted plan: treat what is treatable, then consider whether a behavior medication trial makes sense.

Yes. Selegiline is an MAOI, and clinically important interactions can occur when it is combined with serotonergic medications such as certain antidepressants(Ritter, 1997). This is one reason veterinarians ask for a complete list of prescriptions, supplements, and even occasional “as needed” medications.

Owners should not add or stop behavior medications on their own during a selegiline trial; the interaction risk is part of why it must be supervised.

Side effects can vary, but owners commonly watch for appetite changes, vomiting, restlessness, pacing, or disrupted sleep. Because selegiline can have stimulating metabolites, new agitation is an especially important observation to report(Romberg, 1995).

If severe signs occur—collapse, extreme disorientation, or repeated vomiting—contact a veterinarian urgently rather than waiting for the next scheduled check-in.

Behavior and cognition changes rarely follow a simple timeline. Some cats may show earlier shifts in sleep or vocalizing, while other goals—like fewer litter box accidents—may require environmental changes plus time.

The most useful approach is to agree with the veterinarian on a trial window and specific progress indicators, so the decision is based on observable change rather than hope or frustration.

Log progress indicators that match the household’s main concerns: number of nighttime wake-ups, litter box success rate, pacing or “stuck” episodes, appetite and water intake, and social engagement. Short videos can be helpful when the behavior is hard to describe.

Also log negatives such as vomiting, new hiding, or increased irritability with other pets. These details help the veterinarian decide whether to continue, adjust, or stop the plan.

Safety depends on the cat’s full medical picture and medication list. Many senior cats have kidney disease, thyroid disease, heart disease, or hypertension, and those conditions can change what “safe” looks like for any psychoactive drug.

This is why selegiline decisions should be made after an exam and screening, with a clear monitoring plan and a low threshold to re-check if the cat becomes less predictable or stops eating well.

It depends on what the supplement contains and what other medications the cat takes. “Natural” does not mean interaction-free, and some calming products can affect neurotransmitters or sedation in ways that complicate monitoring.

The safest approach is to tell the veterinarian about every product in the home routine and avoid starting multiple new items at once, so any change in appetite, sleep, or behavior can be interpreted correctly.

Selegiline is an MAOI, which is a different mechanism than many commonly discussed cat behavior medications (such as certain antidepressants or anxiolytics). That difference is important because it changes the interaction profile and the planning around medication combinations.

A veterinarian may choose one option over another based on the cat’s symptoms, other diseases, and whether the household’s main goal is sleep, anxiety reduction, or confusion-related distress.

Dosing should only be provided by a veterinarian who has examined the cat and reviewed all medications. Online dosing advice is risky for MAOI drugs because small differences in the cat’s health status and drug combinations can change safety.

If a veterinarian prescribes it, ask how to give it, what side effects to watch for, and what to do if a dose is missed.

Simple environmental supports often make the biggest day-to-day difference: low-entry litter boxes, night-lights, consistent food and water locations, and blocked-off dead ends where the cat gets trapped. Predictable routines can reduce distress when a cat’s internal “map” is less reliable.

These steps also make medication trials easier to judge, because the cat is less stressed by preventable confusion triggers.

Call urgently if there is collapse, severe weakness, repeated vomiting, sudden extreme agitation, or a rapid change in awareness. Also call if the cat stops eating, because appetite loss in senior cats can quickly become a serious problem.

If the cat is on selegiline and a new medication is prescribed elsewhere (including emergency clinics), make sure the prescribing team knows it is an MAOI so interactions are avoided.

A good decision framework starts with medical screening for look-alike diseases, then a clear statement of goals: what would “calmer, more predictable” look like in this household? Next comes a safety review for interactions and a plan for what to log between vet visits.

Because evidence is limited, the quality of the plan—monitoring, follow-up, and willingness to reassess—matters as much as the drug choice itself.

No. Supplements are not a substitute for diagnosing medical causes of behavior change or for veterinarian-prescribed medications when those are needed. Products such as Hollywood Elixir™ can be discussed as part of a plan that supports normal aging functions, but they should not be treated as a cat dementia medication.

If a cat is on selegiline or other behavior meds, the veterinarian should review any supplement to keep the overall plan clear and safe.